DalsnaFinance

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

Stocks Stocktwits By Stocktwits 13 Jul 2026 02:48 1 min read
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears  Stocktwits

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears Stocktwits

Read the full story on Stocktwits → Opens the original article on news.google.com

Summary aggregated from Stocktwits's public RSS feed. The full reporting belongs to Stocktwits — please read it on their site.